Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
18 pending office actions • 13 clients • 18 examiners • 15 art units • 0 of 18 (0%) have an AI response strategy ready
Florek & Endres PLLC is active in the Biotechnology & Pharmaceuticals technology area. The firm has a career history of 990 applications. There are currently 16 pending office actions being managed by the firm.
The firm reports a resolved allowance rate of 85.1 percent. On average, it takes 3.35 office actions to secure an allowance. These statistics indicate a reliable performance level for clients seeking patent protection in the pharmaceutical industry.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (6%) |
| §103 only | 6 (33%) |
| §112 only | 1 (6%) |
| Double-patenting + other | 2 (11%) |
| Multi-statute (no §101) | 7 (39%) |
| No statute on record | 1 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEONG, NATHAN T | 1 | 71.4% | +24.1% |
| FUBARA, BLESSING M | 1 | 62.2% | +34.3% |
| TRAN, ERIC | 1 | 70.8% | +23.3% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +30.0% |
| LIU, TRACY | 1 | 54.5% | +27.3% |
| PRONZATI, GINA | 1 | 66.7% | +45.9% |
| SHI, KATHERINE MENGLIN | 1 | 78.4% | +21.7% |
| KEENA, ELLA LORRAINE | 1 | 9.1% | +19.4% |
| PRIEST, AARON A | 1 | 61.3% | +25.7% |
| SERGENT, RABON A | 1 | 55.0% | +24.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18429075 | DERMAPLANE RAZOR | KEENA, ELLA LORRAINE | 57d |
| 19045724 | PROCESS FOR PRODUCING THREE-DIMENSIONAL TILES | LEONG, NATHAN T | — |
| 18900122 | ANTIPERSPIRANT CREAM | LIU, TRACY | — |
| 18798138 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | PRONZATI, GINA | — |
| 18580990 | METHOD FOR THE IDENTIFICATION OF THE WHOLE SEQUENCE OF THE VARIABLE REGION OF THE HEAVY AND LIGHT CHAINS OF IMMUNOGLOBULINS | PRIEST, AARON A | — |
| 18578773 | METHOD FOR THE PRODUCTION OF A SHAPE-MEMORY TISSUE AND RELATIVE USES | SERGENT, RABON A | — |
| 17607842 | CONDITIONED MEDIUM AND METHODS OF USE THEREOF | CORDAS, EMILY ANN | — |
| 17393356 | COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | CONNORS, ALEXANDRA F | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18931783 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | TRAN, ERIC | 155d overdue |
| 18790134 | MICRODERMABRASION SYSTEM WITH ERGONOMIC HANDLE | SHI, KATHERINE MENGLIN | 15d |
| 18429075 | DERMAPLANE RAZOR | KEENA, ELLA LORRAINE | 57d |
| 19045724 | PROCESS FOR PRODUCING THREE-DIMENSIONAL TILES | LEONG, NATHAN T | — |
| 18947213 | TOPICAL COMPOSITION AND METHOD OF USE | FUBARA, BLESSING M | — |
| 18919763 | STABLE SOLID FINGOLIMOD DOSAGE FORM | YOUNG, MICAH PAUL | — |
| 18900122 | ANTIPERSPIRANT CREAM | LIU, TRACY | — |
| 18798138 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | PRONZATI, GINA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| AbbVie | 5 |
| Fondazione Irccs Policlinico San Matteo | 2 |
| Altadia Italia S.r.l. | 1 |
| Handa Oncology, LLC | 1 |
| Handa Neuroscience, LLC | 1 |
| Lume Deodorant, LLC | 1 |
| Envy Medical | 1 |
| Harry'S, Inc. | 1 |
| Vertice Pharma LLC | 1 |
| Cardiomix S.r.l. | 1 |
| Luca Dall'Osto | 1 |
| Brain Innovations, S.r.l. | 1 |
| SIFI S.P.A. | 1 |
| Art Unit | Apps |
|---|---|
| 1718 | 1 |
| 1629 | 1 |
| 1614 | 1 |
| 3771 | 1 |
| 3724 | 1 |
| 1681 | 1 |
| 1638 | 1 |
| 3781 | 1 |
| 1644 | 1 |
| 1662 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19045724 | PROCESS FOR PRODUCING THREE-DIMENSIONAL TILES | Altadia Italia S.r.l. | LEONG, NATHAN T | 1718 | §102§103§112 | Non-Final OA | — | Pending | Feb 05, 2025 |
| 18947213 | TOPICAL COMPOSITION AND METHOD OF USE | Allergan Sales, LLC | FUBARA, BLESSING M | §102§103§112DP | Non-Final OA | — | Pending | Nov 14, 2024 | |
| 18931783 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | Handa Oncology, LLC | TRAN, ERIC | 1629 | Other | Non-Final OA | 155d overdue | Pending | Oct 30, 2024 |
| 18919763 | STABLE SOLID FINGOLIMOD DOSAGE FORM | Handa Neuroscience, LLC | YOUNG, MICAH PAUL | §103Other | Non-Final OA | — | Pending | Oct 18, 2024 | |
| 18900122 | ANTIPERSPIRANT CREAM | Lume Deodorant, LLC | LIU, TRACY | 1614 | §101§103§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18798138 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | Allergan Sales, LLC | PRONZATI, GINA | §102§103§112 | Non-Final OA | — | Pending | Aug 08, 2024 | |
| 18790134 | MICRODERMABRASION SYSTEM WITH ERGONOMIC HANDLE | Envy Medical, Inc. | SHI, KATHERINE MENGLIN | 3771 | §112Other | Non-Final OA | 15d | Pending | Jul 31, 2024 |
| 18429075 | DERMAPLANE RAZOR | Harry'S, Inc. | KEENA, ELLA LORRAINE | 3724 | §103§112 | Non-Final OA | 57d | Pending | Jan 31, 2024 |
| 18580990 | METHOD FOR THE IDENTIFICATION OF THE WHOLE SEQUENCE OF THE VARIABLE REGION OF THE HEAVY AND LIGHT CHAINS OF IMMUNOGLOBULINS | Fondazione Irccs Policlinico San Matteo | PRIEST, AARON A | 1681 | §102§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18578773 | METHOD FOR THE PRODUCTION OF A SHAPE-MEMORY TISSUE AND RELATIVE USES | Fondazione Irccs Policlinico San Matteo | SERGENT, RABON A | 1638 | §103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18570437 | ADAPTER FOR CLINICAL, MEDICAL AND LABORATORY CONTAINERS | Vertice Pharma LLC | SMITH, PETER DANIEL | 3781 | §103 | Final Rejection | 31d overdue | Pending | Dec 14, 2023 |
| 18387237 | AUTOANTIBODIES AGAINST NaV1.5 CHANNEL AS BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME AND RELATED THERAPEUTIC METHODS | Cardiomix S.r.l. | OUSPENSKI, ILIA I | 1644 | §112DP | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18279470 | GENETIC STABILIZER AND GROWTH SELECTOR FOR GENETIC TRANSFORMATION OF THE CHLOROPLAST GENOME OF MICROALGAE | Luca Dall'Osto | ZHENG, LI | 1662 | §103 | Final Rejection | 62d | Pending | Aug 30, 2023 |
| 18458248 | Topical Hyperpigmentation Compositions and Method of Use | Allergan Sales, LLC | CAIN, JENNIFER LYNN | 1655 | §103 | Non-Final OA | — | Pending | Aug 30, 2023 |
| 18025092 | METHOD FOR THE MANAGEMENT OF ORAL THERAPY IN PARKINSON'S DISEASE | Brain Innovations, S.r.l. | JACKSON, JORDAN L | 2857 | §103Other | Final Rejection | 155d overdue | Pending | Mar 07, 2023 |
| 17802588 | FORMULATION BASED ON POLYHEXAMETHYLENE BIGUANIDE FOR USE IN THE TREATMENT OF ACANTHAMOEBA KERATITIS AND/OR FUNGAL INFECTIONS | Sifi S.p.A. | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 24d overdue | Pending | Aug 26, 2022 |
| 17607842 | CONDITIONED MEDIUM AND METHODS OF USE THEREOF | Allergan Sales, LLC | CORDAS, EMILY ANN | 1632 | §102§103§112Other | Final Rejection | — | Pending | Oct 29, 2021 |
| 17393356 | COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | Allergan Sales, LLC | CONNORS, ALEXANDRA F | 1634 | §103§112 | Final Rejection | — | Pending | Aug 03, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial